Victory Capital Management Inc. grew its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 65.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,034 shares of the biopharmaceutical company's stock after buying an additional 21,355 shares during the quarter. Victory Capital Management Inc.'s holdings in TG Therapeutics were worth $1,626,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bleakley Financial Group LLC acquired a new position in shares of TG Therapeutics in the 4th quarter valued at approximately $245,000. Castellan Group acquired a new position in TG Therapeutics during the 4th quarter worth approximately $8,539,000. Oppenheimer & Co. Inc. acquired a new position in TG Therapeutics during the 3rd quarter worth approximately $759,000. Segall Bryant & Hamill LLC acquired a new position in TG Therapeutics during the 3rd quarter worth approximately $1,225,000. Finally, Barclays PLC increased its position in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.
TG Therapeutics Trading Up 2.6 %
TGTX traded up $1.10 during trading on Friday, reaching $42.99. 4,649,514 shares of the company's stock were exchanged, compared to its average volume of 2,984,697. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $43.15. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $6.75 billion, a PE ratio of -429.86 and a beta of 2.30. The firm has a fifty day moving average price of $33.17 and a two-hundred day moving average price of $29.63.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO Sean A. Power sold 11,337 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares of the company's stock, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 10.50% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on TGTX shares. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.
View Our Latest Stock Report on TG Therapeutics
About TG Therapeutics
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
